Dr. Kris Discusses Available Targeted Therapies

Video

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies

Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the targeted agents that are available for some of the driver mutations examined in his multicenter study. The trial focused on identifying KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

Kris explains that erlotinib, which targets EGFR, is effective in nearly 20% of lung cancer patients. He anticipates that crizotinib will soon be approved which will be effective in approximately 7% patients. Other drugs, such as trastuzumab for HER2 positive non-small cell lung cancer, are also being developed or investigated for the remaining mutations examined in the trial.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD